| Date Filed | Type | Description |
| 10/04/2023 |
4
| Zeronda Tyler (CFO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,087 shares
@ $3.83, valued at
$4.2k
|
|
| 10/04/2023 |
4
| Stuart Iain (Chief Scientific Officer) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,184 shares
@ $3.83, valued at
$4.5k
|
|
| 10/04/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,154 shares
@ $3.83, valued at
$4.4k
|
|
| 10/04/2023 |
4
| Domzalski David (President and CEO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 8,549 shares
@ $3.83, valued at
$32.7k
|
|
| 07/05/2023 |
4
| Zeronda Tyler (CFO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 91 shares
@ $4.1, valued at
$373.1 |
|
| 07/05/2023 |
4
| Stuart Iain (Chief Scientific Officer) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 151 shares
@ $4.1, valued at
$619.1 |
|
| 07/05/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 157 shares
@ $4.1, valued at
$643.7 |
|
| 07/05/2023 |
4
| Domzalski David (President and CEO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 981 shares
@ $4.1, valued at
$4k
|
|
| 06/02/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Granted 3,664 shares
@ $3.4563, valued at
$12.7k
|
|
| 06/02/2023 |
4
| Domzalski David (President and CEO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Granted 2,766 shares
@ $3.4563, valued at
$9.6k
|
|
| 04/04/2023 |
4
| Zeronda Tyler (CFO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 384 shares
@ $3.08, valued at
$1.2k
|
|
| 04/04/2023 |
4
| Stuart Iain (Chief Scientific Officer) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 480 shares
@ $3.08, valued at
$1.5k
|
|
| 04/04/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 478 shares
@ $3.08, valued at
$1.5k
|
|
| 04/04/2023 |
4
| Domzalski David (President and CEO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 2,734 shares
@ $3.08, valued at
$8.4k
|
|
| 03/22/2023 |
4
| LEPORE PATRICK G (Director) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Bought 20,000 shares
@ $2.484, valued at
$49.7k
|
|
| 03/22/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Bought 10,000 shares
@ $2.5, valued at
$25k
|
|
| 01/04/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,813 shares
@ $0.15, valued at
$272 |
|
| 01/04/2023 |
4
| Stuart Iain (Chief Scientific Officer) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,720 shares
@ $0.15, valued at
$258 |
|
| 01/04/2023 |
4
| Zeronda Tyler (CFO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 354 shares
@ $0.15, valued at
$53.1 |
|
| 01/04/2023 |
4
| Domzalski David (President and CEO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 10,685 shares
@ $0.15, valued at
$1.6k
|
|
| 12/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/04/2022 |
4
| Zeronda Tyler (CFO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 353 shares
@ $0.223, valued at
$78.7 |
|
| 10/04/2022 |
4
| Stuart Iain (Chief Scientific Officer) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,719 shares
@ $0.223, valued at
$383.3 |
|
| 10/04/2022 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,813 shares
@ $0.223, valued at
$404.3 |
|
| 10/04/2022 |
4
| Domzalski David (President and CEO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 10,683 shares
@ $0.223, valued at
$2.4k
|
|
| 08/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/05/2022 |
4
| Zeronda Tyler (CFO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 354 shares
@ $0.389, valued at
$137.7 |
|
| 07/05/2022 |
4
| Stuart Iain (Chief Scientific Officer) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,719 shares
@ $0.389, valued at
$668.7 |
|
| 07/05/2022 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,813 shares
@ $0.389, valued at
$705.3 |
|
| 07/05/2022 |
4
| Domzalski David (President and CEO) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 10,683 shares
@ $0.389, valued at
$4.2k
|
|
|